Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2014, Article ID 584513, 6 pages
http://dx.doi.org/10.1155/2014/584513
Case Report

Metastatic Follicular Thyroid Carcinoma Secreting Thyroid Hormone and Radioiodine Avid without Stimulation: A Case Report and Literature Review

1Department of Geriatrics, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
2Department of Otolaryngology-Head and Neck Surgery, Thyroid Center, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
3Department of Geriatrics, Department of Otolaryngology-Head and Neck Surgery, Thyroid Center, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA

Received 24 February 2014; Revised 21 July 2014; Accepted 15 September 2014; Published 7 October 2014

Academic Editor: Hidetoshi Ikeda

Copyright © 2014 Syed A. Abid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. R. McHenry and R. Phitayakorn, “Follicular adenoma and carcinoma of the thyroid gland,” The Oncologist, vol. 16, no. 5, pp. 585–593, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Thyroid Cancer, Updated 2013, http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-what-is-cancer.
  3. R. M. Tuttle, “Differentiated thyroid cancer: overview of management,” 2013, http://www.uptodate.com/contents/differentiated-thyroid-cancer-overview-of-management.
  4. M. Tardy, E. Tavernier, G. Sautot et al., “A case of hyperthyroidism due to functioning metastasis of differentiated thyroid carcinoma. Discussion and literature review,” Annales d'Endocrinologie, vol. 68, no. 1, pp. 39–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Ikejiri, M. Furuyama, T. Muranaka et al., “Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis,” Clinical Nuclear Medicine, vol. 22, no. 4, pp. 227–230, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. W. D. Bowden and R. E. Jones, “Thyrotoxicosis associated with distant metastatic follicular carcinoma of the thyroid,” Southern Medical Journal, vol. 79, no. 4, pp. 483–486, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. S. J. Paul and J. C. Sisson, “Thyrotoxicosis caused by thyroid cancer,” Endocrinology and Metabolism Clinics of North America, vol. 19, no. 3, pp. 593–612, 1990. View at Google Scholar · View at Scopus
  8. A. Boucher, R. Matte, R. Belanger et al., “Suppression of T4 secretion in a metastatic follicular carcinoma,” Clinical and Investigative Medicine, vol. 12, no. 3, pp. 162–164, 1989. View at Google Scholar · View at Scopus
  9. P. B. Ottevanger, A. R. M. M. Hermus, A. G. H. Smals, and P. W. C. Kloppenborg, “TSH-dependent production of T4 and T3 by metastases of a thyroid carcinoma,” Acta Endocrinologica, vol. 127, no. 5, pp. 413–415, 1992. View at Google Scholar · View at Scopus
  10. M. Lang and M. Flesch, “T3 hyperthyroidism with metastatic follicular thyroid carcinoma under substitution therapy,” NuklearMedizin, vol. 35, no. 5, pp. 186–189, 1996. View at Google Scholar · View at Scopus
  11. E. Brecelj, S. F. Grazio, M. Auersperg, and M. Bračko, “Prognostic value of E-cadherin expression in thyroid follicular carcinoma,” European Journal of Surgical Oncology, vol. 31, no. 5, pp. 544–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Kato, T. Tsuchiya, G. Tamura, and T. Motoyama, “E-cadherin expression in follicular carcinoma of the thyroid,” Pathology International, vol. 52, no. 1, pp. 13–18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Garcia-Rostan, R. L. Camp, A. Herrero, M. L. Carcangiu, D. L. Rimm, and G. Tallini, “β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis,” The American Journal of Pathology, vol. 158, no. 3, pp. 987–996, 2001. View at Publisher · View at Google Scholar · View at Scopus